Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D‐VCd) in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). Patients received 4–8 induction cycles of bortezomib 1·5 mg/m(2), cyclophosphamide 300 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yimer, Habte, Melear, Jason, Faber, Edward, Bensinger, William I., Burke, John M., Narang, Mohit, Stevens, Don, Gunawardena, Sriya, Lutska, Yana, Qi, Keqin, Ukropec, Jon, Qi, Ming, Lin, Thomas S., Rifkin, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593455/
https://www.ncbi.nlm.nih.gov/pubmed/30828799
http://dx.doi.org/10.1111/bjh.15806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593455/
https://www.ncbi.nlm.nih.gov/pubmed/30828799
http://dx.doi.org/10.1111/bjh.15806

Ejemplares similares